This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Andrew A. Skolnick

JAMA. 1998;280:10-11.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THE SECURITIES Exchange Commission (SEC) is cracking down on biomedical researchers who illegally use insider information to help themselves or others profit in the stock market.

On June 8, the US District Court for the Central District of California sentenced Roger D. Wyatt, a former consultant to Chantal Pharmaceutical Corporation, of Los Angeles, Calif, to 15 months in prison and ordered him to pay a $20000 fine for committing perjury during an insider trading investigation and civil suit brought by the SEC. In November 1997, the commission obtained a final judgment against Wyatt, who lives in Houston, Tex, for allegedly using insider information about the unfavorable results of a clinical trial of the company's acne medication to sell his stock in the company and to tip off a friend who sold his. The judgment requires Wyatt to pay more than $260000 in civil penalties and other fines.

. . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?